近日,东南大学附属中大医院副院长、放射科主任居胜红教授团队在权威期刊《Nano Today》(IF 17.4)发表了题为“Acidic Tumor Microenvironment-Activated MRI Nanoprobes for Modulation and Visualization of Anti-PD-L1 Immunotherapy”的研究成果。研究构建了一种新型pH响应性磁共振探针,探讨了pH调节对胰腺癌肿瘤免疫微环境...
ImmunotherapyPD-L1/PD-1Immune checkpoint inhibitorTumor immune therapy, especially anti-programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) treatment, is currently the focus of substantial attention. Ovarian cancer is the leading cause of mortality from gynecological malignancies, and...
Online literature searches were performed via PubMed, PubMed Central, and Google using the keywords “immune checkpoint inhibition”; “host-directed therapy”; “T cell exhaustion”; “cancer immunotherapy”; “anti-PD-1 therapy”; “anti-PD-L1 therapy”; “chronic infections”; “antigen-specif...
2021年5月26日讯/生物谷/BIOON/---近日,澳门科技大学在Gut杂志上发表了题为"Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti- PD-1/PD- L1) immunotherapy"的研究性文章。
Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer:the era of immunotherapy. Valecha G K,Vennepureddy A,Ibrahim U,et al. Expert Review of Anticancer Therapy . 2017Valecha, G. K. et al. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. ...
2023年11月02日,哥伦比亚大学爱尔文医学中心的研究人员在Cancer Cell期刊发表了题为:Anti-PD-1immunotherapywith androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer的研究文章。 与其他恶性肿瘤相比,原发性和去势抵抗性前列腺癌(CRPC)的肿瘤微环境(TME)相对...
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Programmed cell death 1 (PD-1)/programmed cell death 1 ligand (PD-L1) blockade has shown promising effects in cancer immunotherapy. Removing the so-called ... Mengjia,Song,Xinfeng,... - Chinese journal of...
PDâL1renal cell carcinomaImmunotherapy based on blockade of the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has shown promising clinical activity for renal cell carcinoma (RCC) patients; however, the most effective use of these agents in combination with ...
摘要: 程序性细胞死亡-1 (PD-1) 免疫检查点抑制剂在多种肿瘤中显示出良好的疗效。在这里,我们报告一个不可切除的局部进展期胃癌 (GC) 与程序性细胞死亡 ligand-1 (PD-L1) 阳性和微卫星不稳定 (MSI),作为一线治疗方案,单剂量的 anti-PD-1 联合化疗治疗后,病理完全缓解 (pCR) 表现出意想不到的疗效。一...
CPD-1 Immunotherapy PD-L1 Studied as Biomarker for Anti–PD-1 ImmunotherapyPD-L1 Studied as Biomarker for Anti–PD-1 ImmunotherapyAlice Goodman